Nedocromil

Nedocromil

SCHEMBL371456

CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1.CCCc1c2oc(C(=O)O)cc(=O)c2cc2c(=O)cc(C(=O)O)n(CC)c12

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Nedocromil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PDE4D known ✓ Q08499 1/20 0.59
TBK1 Q9UHD2 20/20 0.59
IKBKE Q14164 10/20 0.59
KDM4E B2RXH2 1/20 0.59
NPC1 O15118 1/20 0.59
ABCC4 O15439 1/20 0.59
TTR P02766 1/20 0.59
GAA P10253 1/20 0.59
PKM P14618 1/20 0.59
ADRA1A P35348 1/20 0.59
OPRD1 P41143 1/20 0.59
RAB9A P51151 1/20 0.59
PDE3A Q14432 1/20 0.59
GPR35 Q9HC97 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nedocromil SCHEMBL29406688 0.78 PDE5A (0.47) KDM4EPKMGPR35
Nedocromil SCHEMBL4611 0.78 PDE5A (0.47) KDM4EPKMGPR35
Nedocromil SCHEMBL28341341 0.77 PDE5A (0.46) KDM4EPKMGPR35
Nedocromil SCHEMBL2879046 0.77 PDE5A (0.46) KDM4EPKMGPR35
Nedocromil SCHEMBL20481863 0.77 PDE5A (0.46) KDM4EPKMGPR35
Nedocromil SCHEMBL316743 0.77 PDE5A (0.46) KDM4EPKMGPR35
Nedocromil SCHEMBL667050 0.77 PDE5A (0.46) KDM4EPKMGPR35
Nedocromil SCHEMBL24943 0.77 PDE5A (0.46) KDM4EPKMGPR35
Amlexanox SCHEMBL5058549 0.77 TBK1 (1.00) TBK1IKBKEKDM4ENPC1ABCC4
Amlexanox SCHEMBL29642 0.77 TBK1 (1.00) TBK1IKBKEKDM4ENPC1ABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4400163-A1 COMPOSITIONS FOR THE TREATMENT OF GLUTEN INTOLERANCE AND USES THEREOF Glutagen Pty Ltd (AU) 2024-07-17 EP disclosed
US-20240026331-A1 RECOMBINANT NEPROSIN POLYPEPTIDES AND METHODS OF EXPRESSION CODEXIS, INC. 2024-01-25 US disclosed
WO-2023220658-A2 RECOMBINANT NEPROSIN POLYPEPTIDES AND METHODS OF EXPRESSION CODEXIS, INC. (US) 2023-11-16 WO disclosed
US-11725198-B2 Treatment of gluten intolerance and related conditions CODEXIS, INC. (US) 2023-08-15 US disclosed
US-11723960-B2 Compositions and methods for treating gluten intolerance and disorders arising therefrom CODEXIS, INC. (US) 2023-08-15 US disclosed
US-11701411-B2 Compositions and methods for treating gluten intolerance and disorders arising therefrom CODEXIS, INC. (US) 2023-07-18 US disclosed
US-20230173040-A1 METHODS AND COMPOSITIONS FOR ATI DIGESTION GLUTAGEN PTY LTD (AU) 2023-06-08 US disclosed
EP-4149520-A1 METHODS AND COMPOSITIONS FOR ATI DIGESTION Glutagen Pty Ltd (AU) 2023-03-22 EP disclosed
EP-3943104-A1 COMPOSITIONS AND METHODS FOR TREATING GLUTEN INTOLERANCE AND DISORDERS ARISING THEREFROM Codexis, Inc. (US) 2022-01-26 EP disclosed
WO-2021226672-A1 METHODS AND COMPOSITIONS FOR ATI DIGESTION GLUTAGEN PTY LTD (AU) 2021-11-18 WO disclosed
US-20080095710-A1 ENZYME TREATMENT OF FOODSTUFFS FOR CELIAC SPRUE The Board of Trustees of the Leland Stanford Junior University & Celiac Spruce Research 2008-04-24 US disclosed
US-7320788-B2 Enzyme treatment of foodstuffs for Celiac Sprue THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2008-01-22 US disclosed
US-7303871-B2 Administering glutenase to Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating damaging effects of gluten THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2007-12-04 US disclosed
EP-1740197-A1 THERAPEUTIC ENZYME FORMULATIONS AND USES THEREOF Celiac Sprue Research Foundation (US) 2007-01-10 EP disclosed
US-20060002917-A1 Effect of prolyl endopeptidase on digestive-resistant gliadin peptides in vivo THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2006-01-05 US disclosed
WO-2005107786-A1 THERAPEUTIC ENZYME FORMULATIONS AND USES THEREOF CELIAC SPRUE RESEARCH FOUNDATION (US) 2005-11-17 WO disclosed
US-20050249719-A1 Enzyme treatment of foodstuffs for Celiac Sprue THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2005-11-10 US disclosed
EP-1572127-A2 ENZYME TREATMENT OF FOODSTUFFS FOR CELIAC SPRUE The Board of Trustees of The Leland Stanford Junior University (US) 2005-09-14 EP disclosed
US-20030215438-A1 Administering glutenase to Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating damaging effects of gluten BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE 2003-11-20 US disclosed
WO-2003068170-A2 ENZYME TREATMENT OF FOODSTUFFS FOR CELIAC SPRUE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2003-08-21 WO disclosed